Announcement

7
JUNE
2019


Category Label


Client Announcements

Microsaic Systems : Distribution Agreement with CM Corporation Ltd.

  •  
  •   07 June 2019

RNS Number : 4405B

Microsaic Systems plc

07 June 2019

 

7 June 2019

Microsaic Systems plc

 

("Microsaic" or the "Company")

 

Distribution Agreement with CM Corporation Ltd.

 

Microsaic Systems plc (AIM: MSYS), the developer of point of need mass spectrometry ("MS") instruments, is pleased to announce that it has signed a distribution agreement with CM Corporation Ltd ("CM-C") for the exclusive distribution of the Microsaic 4500 MiD® MS detector in South Korea.

 

Established in 2000, CM-C is a specialist distributor of life science and analytical equipment, covering a wide range of markets in South Korea, including natural products, organic synthesis, pharmaceuticals, foods and environmental.

 

Glenn Tracey, CEO of Microsaic, commented, "We are very pleased to partner with CM-C in South Korea. In particular, the team at CM-C has the in-depth technical expertise in two key areas of interest for us: reaction monitoring and thin layer chromatography.

 

"Online MS can enable rapid chemical quantification (<1 min analysis duration), for desired compounds and intermediates. MS can provide a greater degree of structural information and product composition, compared with optical spectroscopy, all in real-time due to its short method times. Consequently, MS is becoming the analytical technique of choice for optimising an automated flow reactor, as the technique determines steady state and then calculates a product yield with minimal data manipulation. Furthermore, Microsaic's MS technology is specifically designed for point of need applications.

 

"Estimates of the global market size for the reaction monitoring equipment market are in the region of $1.5 billion by 2022, with leading annual growth rates in Asia Pacific.

 

"We work exclusively with local partners, knowledgeable in separation and MS technologies. Our strategy continues to be focused on business development in all key geographies."

 

Mo Hoyule, Managing Director of CM-C, added: "We are delighted to be distributing Microsaic's technology, alongside globally recognised brands such as CAMAG and ThalesNano. This will enable us to offer our customers in South Korea a total solution in some very exciting growth areas in on-line chemical monitoring."

 

This distribution agreement is the tenth partner signing for Microsaic, further extending its geographic reach.

 

Enquiries:

 

 

Microsaic Systems plc

Glenn Tracey, CEO

Bevan Metcalf, FD

+44 (0) 1483 751 577

 

N+1 Singer (Nominated Adviser & Broker)

Shaun Dobson (Corporate Finance)

Tom Salvesen (Corporate Broking)

 

 

+44 (0)20 7496 3000

IFC Advisory Ltd (Financial PR)

Graham Herring

Heather Armstrong

Florence Chandler

+44 (0)20 3934 6630

 

 

About Microsaic Systems

Microsaic Systems plc (AIM: MSYS) is a high technology company developing chip-based, bench-top and point-of-analysis mass spectrometry ("MS") instruments that are designed to improve the efficiency of pharmaceutical R&D and manufacturing. The Company is working with established global life science companies to co-develop new solutions to improve productivity in the development of small molecule and novel biologic (peptides, antibodies) medicines. MS is a powerful method of analysis to enable earlier decision making relating to product identification, purity and bioactivity, and is the analytical technique of choice for biochemists across many industry sectors.

 

Microsaic's core product, the 4500 MiD®, is a robust and compact MS system, retaining the functionality of larger conventional MS systems, is easier to use by non-specialists, consumes less energy and has lower running costs. For more information, please go to www.microsaic.com.  

 

 

 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

 

END

 

 

CNTLLFVERSIRIIA

;